Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Dechant

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Cancer Science|July 2, 2011
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)Katja Klausz, Sven Berger, Jeroen J Lammerts van Bueren, et al.
Cancer Research|July 3, 2008
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodiesMichael Dechant, Wencke Weisner, Sven Berger, et al.
Blood|June 3, 2004
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasJessica L Teeling, Ruth R French, Mark S Cragg, et al.
Blood|June 21, 2008
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cellsMatthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, et al.
Journal of Immunological Methods|August 23, 2011
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCCRoland Repp, Christian Kellner, Anja Muskulus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineageTanja Schneider-Merck, Jeroen J Lammerts van Bueren, Sven Berger, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
EMBO Molecular Medicine|August 7, 2013
IgA EGFR antibodies mediate tumour killing in vivoPeter Boross, Stefan Lohse, Maaike Nederend, et al.
British Journal of Haematology|April 28, 2017
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicityStefan Lohse, Sebastian Loew, Anna Kretschmer, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cancer Science|July 2, 2011
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)Katja Klausz, Sven Berger, Jeroen J Lammerts van Bueren, et al.
Cancer Research|July 3, 2008
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodiesMichael Dechant, Wencke Weisner, Sven Berger, et al.
Blood|June 3, 2004
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasJessica L Teeling, Ruth R French, Mark S Cragg, et al.
Blood|June 21, 2008
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cellsMatthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, et al.
Journal of Immunological Methods|August 23, 2011
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCCRoland Repp, Christian Kellner, Anja Muskulus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineageTanja Schneider-Merck, Jeroen J Lammerts van Bueren, Sven Berger, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
EMBO Molecular Medicine|August 7, 2013
IgA EGFR antibodies mediate tumour killing in vivoPeter Boross, Stefan Lohse, Maaike Nederend, et al.
British Journal of Haematology|April 28, 2017
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicityStefan Lohse, Sebastian Loew, Anna Kretschmer, et al.
Pageof 3